Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Hansoh Acquires China Rights to Osteoarthritis Therapy in Deal Worth $63 Million-Plus

publication date: Sep 27, 2022

Shanghai Hansoh Pharma acquired Greater China rights to an injection for osteoarthritis of the knee from Belgium’s KiOmed Pharma. KiOmedinevsOne is a novel highly purified polysaccharide based on a mushroom that is administered by injection. Unlike hyaluronic acid, the therapy has a dual mechanism that reduces oxidative stress and increases lubrication of the joint. Hansoh will make an unspecified upfront payment and be responsible for up to $63 million in milestones, plus royalties on sales. KiOmedinevsOne, an animal-free product, was approved for EU use last year. More details....

Stock Symbol: (HK: 3692)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China